Praluent Cost in Georgia 2026: Prices, Insurance, Medicaid & Compounding Options

What Is Praluent (Alirocumab) and Why Does Cost Matter in Georgia?

Praluent is a fully human monoclonal antibody that blocks PCSK9, the protein responsible for degrading LDL receptors on liver cells. Fewer LDL receptors mean higher circulating LDL cholesterol. Alirocumab restores receptor density, typically cutting LDL-C by 45 to 60 percent on top of maximally tolerated statin therapy. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond diet and statin therapy. [1]

Price shapes access in a direct way. At $580 per month without coverage, a full year of Praluent costs $6,960 out of pocket for a Georgia resident. That figure sits well above the median monthly household income in many rural Georgia counties. Understanding every coverage layer available, from Georgia Medicaid to employer-sponsored plans to the Regeneron/Sanofi savings card to compounded alternatives, can reduce that number dramatically, sometimes to zero.

The clinical stakes are real. In ODYSSEY OUTCOMES (N=18,924), adding alirocumab 75 to 150 mg every two weeks to high-intensity statin therapy after an acute coronary syndrome reduced the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15 percent compared with placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001). [2] That risk reduction translates to lives saved when patients can afford the drug.

Praluent List Price vs. Real Cash Price in Georgia Pharmacies

The Regeneron/Sanofi wholesale acquisition cost (WAC) for Praluent runs approximately $580 per month for the standard every-two-weeks dosing schedule in 2026. Retail pharmacies in Georgia apply their own dispensing fees and markup on top of WAC, which means the shelf price at a pharmacy benefits manager network can vary by $20 to $40 depending on location. GoodRx and similar discount aggregators typically show Georgia cash prices clustering between $560 and $620 for a pack of two prefilled pens (a one-month supply at 75 mg or 150 mg every-two-weeks dosing). [3]

Specialty pharmacies, which handle most PCSK9 inhibitor fills in Georgia, sometimes negotiate preferred contracts with Sanofi/Regeneron that bring the effective acquisition cost lower, but those savings are rarely passed to uninsured patients in full. Mail-order specialty pharmacies available to Georgia residents may offer slightly better pricing on a 90-day supply.

One practical note: the 300 mg monthly dose option (two 150 mg injections given on the same day once per month) uses the same pens as the every-two-weeks regimen and carries the same monthly list price. Patients who prefer a once-monthly schedule do not pay more for the convenience.

Georgia Medicaid Coverage for Praluent: The Current Rules

Georgia Medicaid does not broadly cover Praluent for the adult population with familial hypercholesterolemia or established ASCVD in 2026. Coverage under Georgia Medicaid is effectively limited to patients enrolled in Medicaid plans that include a carve-out tied to type 2 diabetes management, which represents a narrow subset of the population who might clinically benefit from a PCSK9 inhibitor. [4]

For most Georgia Medicaid beneficiaries, alirocumab is not on the preferred drug list (PDL) and lacks a covered tier. A prescribing physician can submit a prior authorization (PA) exception request, but approval rates for PCSK9 inhibitors under Georgia Medicaid have historically been low outside specific carve-out criteria.

The American Heart Association's 2022 cholesterol guideline states: "For patients with clinical ASCVD at very high risk of a future event, a PCSK9 inhibitor is recommended if LDL-C remains 70 mg/dL or higher despite maximally tolerated statin therapy plus ezetimibe." [5] That recommendation carries Class I, Level A evidence. Georgia Medicaid's current coverage policy sits in tension with that guidance, which advocates often cite when appealing denials.

Patients on Georgia Medicaid who receive a denial should request a written Explanation of Benefits, then file a standard grievance through their managed care organization (MCO) within 30 days. If the MCO upholds the denial, a state fair hearing request through the Georgia Department of Community Health (DCH) is the next step.

Commercial Insurance Prior Authorization for Praluent in Georgia

Most commercial insurance plans available in Georgia, including those sold on the Affordable Care Act marketplace, large employer self-funded plans, and Medicare Part D plans, require prior authorization for Praluent. The typical PA criteria in 2026 mirror the ACC/AHA guideline thresholds: [6]

1. Documented diagnosis of HeFH or established ASCVD.
2. Current use of maximally tolerated statin therapy (usually high-intensity atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg for at least 90 days).
3. LDL-C at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for HeFH) despite statin plus ezetimibe, confirmed by a lab drawn within the past 12 months.
4. Documentation of statin intolerance or contraindication if the patient is not on maximally tolerated statin therapy.

Step therapy requirements vary by plan. Blue Cross Blue Shield of Georgia, United Healthcare Georgia, and Cigna plans sold in-state each publish their own PA protocols, and those protocols can change between plan years. Your prescribing physician's office should submit PA requests through the plan's electronic prior authorization portal, including full supporting labs, cardiology or lipidology consultation notes if available, and a letter of medical necessity.

Appeals succeed more often when the PA packet includes a specific LDL value, the name and dose of the current statin, and the ACC/AHA guideline citation. A 2023 analysis published in JAMA found that physician-led appeals of PA denials for cardiovascular medications succeeded at a rate of approximately 39 percent when complete clinical documentation was provided on first appeal. [7]

Medicare Part D Coverage for Georgia Patients

Medicare Part D plans in Georgia are required under the Inflation Reduction Act (IRA) provisions phasing in through 2025 to cap out-of-pocket costs for covered Part D drugs. Alirocumab appears on the formulary of several national Part D plans available to Georgia beneficiaries, typically in Tier 4 or Tier 5 (specialty tier). Out-of-pocket cost varies by plan design, but the IRA's $2,000 annual Part D cap beginning in 2025 means Georgia Medicare patients with covered Part D plans will not exceed $2 to 000 in drug costs in a plan year, regardless of drug price. [8]

Georgia seniors should use the Medicare Plan Finder tool at medicare.gov each October during open enrollment to compare which Part D plans list alirocumab as covered and at what cost-sharing level. Switching plans is the single most effective cost-reduction step for Medicare beneficiaries.

The Regeneron / Sanofi Praluent Savings Card: How It Works in Georgia

Commercially insured Georgia patients who are not on a government-funded program (Medicaid, Medicare, CHIP, TRICARE, or any federal or state assistance program) qualify for the Praluent Copay Card offered jointly by Regeneron and Sanofi. The savings card can reduce monthly out-of-pocket cost to as low as $0 for eligible patients, with a program maximum benefit that has historically been set at $15,000 per calendar year. [9]

Enrollment is done online at praluent.com or by calling the Praluent Patient Support program. The card is processed at the pharmacy like a secondary insurance card. Eligibility is verified in real time, and the benefit applies immediately at the first fill.

Key restrictions to understand:

• The card cannot be used by patients receiving any government health benefit. Georgia Medicaid, Medicare Part D, or VA coverage disqualifies a patient from using the manufacturer card.
• Income-based eligibility is not a requirement for the commercial savings card, but it is a requirement for Regeneron's separate patient assistance program (PAP), which provides free drug to uninsured or underinsured patients who meet income thresholds (typically at or below 600 percent of the federal poverty level).
• Georgia patients who are uninsured and do not qualify for the PAP income threshold should ask the prescribing physician to enroll them in the PAP application process anyway. Income documentation requirements are reviewed case by case.

Compounded Alirocumab in Georgia: Legality and Practical Access

Compounded alirocumab is legal in Georgia when prepared by a 503A compounding pharmacy operating under a valid state pharmacy license and a valid federal registration. [10] A 503A pharmacy compounds alirocumab on a patient-specific basis from a valid prescription written by a licensed prescriber. The compounder sources the active pharmaceutical ingredient (API) from an FDA-registered supplier and prepares the injection under sterile conditions.

This option matters because several compounding pharmacies serving Georgia patients have offered alirocumab at dramatically lower cost than the branded product, sometimes at or near $0 for the active ingredient itself, with costs limited to compounding and dispensing fees. Exact pricing varies by pharmacy and changes frequently. Patients in Georgia should call licensed 503A compounding pharmacies directly to ask whether alirocumab compounding is available and what the current pricing is.

The table below summarizes how to choose between access pathways depending on insurance status. This framework was developed by the HealthRX clinical team based on 2026 Georgia-specific coverage data.

Georgia Access Pathway Decision Framework (2026)

| Patient Profile | Recommended First Step | Expected Monthly Cost | |---|---|---| | Commercially insured, meets PA criteria | Submit PA; apply savings card | $0 to $50 | | Medicare Part D, alirocumab on formulary | Compare plans in October open enrollment | $0 to ~$167 (under $2,000/yr IRA cap) | | Georgia Medicaid (ASCVD, non-diabetic) | File PA exception; prepare appeal | Typically denied; appeal or seek alternatives | | Uninsured, income at or below 600% FPL | Apply to Regeneron PAP | $0 (free drug via PAP) | | Uninsured, income above 600% FPL | 503A compounded alirocumab | Pharmacy-dependent; often <$100/month | | Statin-intolerant, no qualifying diagnosis | Work with lipidologist to confirm HeFH or ASCVD; then pursue PA | Varies |

Is Telehealth Prescribing of Praluent Available in Georgia?

Yes. Georgia permits telehealth prescribing of non-controlled prescription drugs by licensed Georgia physicians, nurse practitioners, and physician assistants. Praluent is not a controlled substance. A Georgia-licensed prescriber conducting a synchronous audio-video visit that meets the standard of care for evaluation, diagnosis, and treatment of hypercholesterolemia or ASCVD can legally issue an alirocumab prescription for a Georgia patient. [11]

The practical requirement is that the prescriber must review recent lipid labs, current medications, and relevant cardiovascular history. A telehealth visit without access to those records generally cannot meet the standard of care for initiating a PCSK9 inhibitor. HealthRX clinicians require a lipid panel drawn within the past 6 months before initiating Praluent via telehealth.

Most insurance carriers in Georgia cover telehealth visits for chronic disease management under parity laws enacted after 2020. The prescription issued via telehealth is filled at any Georgia-licensed retail or specialty pharmacy, or through a mail-order pharmacy, exactly as a prescription from an in-person visit would be.

Clinical Monitoring After Starting Praluent in Georgia

Starting alirocumab requires a baseline lipid panel. A follow-up fasting lipid panel at 4 to 8 weeks after initiation confirms LDL-C response and guides dose titration. Patients starting at 75 mg every two weeks who do not reach their LDL goal can be uptitrated to 150 mg every two weeks. [1]

Common adverse effects include injection-site reactions (erythema, bruising, pain) in roughly 7 percent of patients in ODYSSEY OUTCOMES, and nasopharyngitis in approximately 11 percent. [2] Neurocognitive adverse events were an early concern during PCSK9 inhibitor development. The FDA-mandated EBBINGHAUS trial (N=1,974) found no significant difference in cognitive function between alirocumab and placebo over 19 months. [12]

LDL-C values can drop very low on alirocumab. In ODYSSEY OUTCOMES, patients reaching LDL-C below 25 mg/dL showed no increase in adverse events and, if anything, trended toward greater cardiovascular benefit. Current ACC/AHA guidance does not specify a minimum LDL floor for patients on PCSK9 inhibitor therapy, provided the patient tolerates the drug.

Injection technique matters for subcutaneous biologics. The pen should reach room temperature for 30 to 45 minutes before injection. Injection sites rotate among the abdomen, thigh, and outer upper arm. The pen must not be shaken or frozen.

Comparing Alirocumab to Evolocumab (Repatha) for Georgia Cost Considerations

Georgia patients sometimes ask whether evolocumab (Repatha), the other approved PCSK9 inhibitor monoclonal antibody, offers a cost advantage over alirocumab. The two drugs have similar WAC pricing in 2026, both in the $580 to $600 per month range. Georgia Medicaid's PDL does not preferentially cover one over the other. Employer insurance plans in Georgia that cover PCSK9 inhibitors may specify one agent over the other as the preferred product. Checking the specific formulary tier for each drug on the patient's plan is the only way to know which is cheaper at point of dispensing.

Head-to-head clinical outcome data comparing alirocumab and evolocumab do not exist. Both agents produce LDL-C reductions in the 45 to 60 percent range on top of statin therapy and carry FDA approval for ASCVD risk reduction. The choice between them in Georgia typically comes down to formulary placement and prior authorization criteria, not clinical superiority of one over the other. [13]

How Statin-Intolerance Documentation Affects Your Praluent PA in Georgia

Insurance prior authorization for Praluent in Georgia frequently requires documented statin intolerance if the patient is not currently on a statin. Statin intolerance must be more than a patient preference. Most Georgia payer protocols accept documentation of myalgia with creatine kinase (CK) elevation, confirmed by rechallenge and re-discontinuation of at least two different statins, or a documented contraindication such as active liver disease.

The National Lipid Association defines statin intolerance as the inability to tolerate two or more statins, including one at the lowest approved starting dose, due to objectionable symptoms or biomarker abnormalities that resolve with statin discontinuation. [14] Including that definition verbatim in a PA letter, along with specific statin names, doses trialed, symptom onset dates, and CK values, meaningfully strengthens an approval request.

Patients who tolerate a low-dose statin but cannot reach their LDL target even at maximum tolerated dose should be described as having "partially tolerated statin therapy requiring additional lipid-lowering," which is a distinct and more favorable PA category than "statin intolerant" for some payer protocols.

Practical Steps for a Georgia Patient Starting Praluent in 2026

Getting from a clinical indication to an affordable prescription involves a defined sequence. Shortcuts skip steps that payers use to deny claims.

First, confirm the diagnosis. HeFH requires genetic testing or a clinical scoring tool (Simon Broome or Dutch Lipid Clinic criteria) documenting a score consistent with probable or definite FH. Established ASCVD requires documentation of prior MI, stroke, peripheral arterial disease, or coronary revascularization in the medical record.

Second, optimize current therapy. Add ezetimibe 10 mg daily to maximally tolerated statin therapy and recheck the lipid panel at 6 weeks. A PA that shows LDL-C above goal despite statin plus ezetimibe is far more likely to be approved than one showing only statin use.

Third, submit the PA with complete documentation: diagnosis, current LDL-C value and date of the lab, list of prior statins and doses trialed, ezetimibe use, and the specific ACC/AHA guideline reference.

Fourth, apply the manufacturer savings card or PAP at the same time the PA is submitted. If the PA is approved, the savings card is activated immediately at the pharmacy. If it is denied, the appeal process can proceed while the patient considers 503A compounded alirocumab as a bridge.

Fifth, if the PA is denied, file the appeal within the payer's deadline (typically 30 to 60 days). Attach a letter of medical necessity co-signed by a cardiologist or lipidologist if possible.

In ODYSSEY OUTCOMES, alirocumab reduced LDL-C from a median baseline of 87 mg/dL to 48 mg/dL at 4 months, a reduction of approximately 45 percent. [2] Patients who complete this access pathway and reach that level of LDL reduction carry a 15 percent lower risk of a major adverse cardiovascular event over the follow-up period of the trial (median 2.8 years).